1α-Hydroxyvitamin D2 inhibits growth of human neuroblastoma

Journal of Neuro-Oncology

Volumn 85, Issue 3, 2007, Pages 255-262

  van Ginkel, Paul R ^a   Yang, William ^a   Marcet, Marcus M ^a   Chow, Clement C ^a   Kulkarni, Amol D ^a   Darjatmoko, Soesiawati ^a   Lindstrom, Mary J ^a   Lokken, Janice ^a   Bhattacharya, Saswati ^a   Albert, Daniel M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Doxercalciferol; Neuroblastoma; Serum calcium; Vitamin D analog; Xenograft model

Indexed keywords

CALCITRIOL; CALCIUM; DOXERCALCIFEROL; DRUG METABOLITE; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MORTALITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TOXICITY TESTING; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CALCIUM; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ERGOCALCIFEROLS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEUROBLASTOMA; RANDOM ALLOCATION; RECEPTORS, CALCITRIOL; TRANSPLANTATION, HETEROLOGOUS;

EID: 36348994279     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9418-z     Document Type: Article

References (45)

1. van Noesel MM, Versteeg R (2004) Pediatric neuroblastomas: Genetic and epigenetic 'danse macabre'. Gene 325:1-15
2. Bown N (2001) Neuroblastoma tumour genetics: Clinical and biological aspects. J Clin Pathol 54(12):897-910
3. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS (1999) Cancer surveillance series: Recent trends in childhood cancer incidence and mortality in the united states. J Natl Cancer Inst 91(12):1051-1058
4. Weinstein JL, Katzenstein HM, Cohn SL (2003) Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8(3):278-292
5. Gestblom C, Hoehner JC, Hedborg F, Sandstedt B, Pahlman S (1997) In vivo spontaneous neuronal to neuroendocrine lineage conversion in a subset of neuroblastomas. Am J Pathol 150(1):107-117
6. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B et al (1999) The international neuroblastoma pathology classification (the shimada system). Cancer 86(2):364-372
7. Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S et al (2001) Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19(12):3080-3090
8. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. children's cancer group. N Engl J Med 341(16):1165-1173
9. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M (1996) Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334(4):231-238
10. Berthold F, Hero B (2000) Neuroblastoma: Current drug therapy recommendations as part of the total treatment approach. Drugs 59(6):1261-1277
11. Kushner BH, Cheung NK, Kramer K, Heller G, Jhanwar SC (1998) Neuroblastoma and treatment-related myelodysplasia/leukemia: The memorial sloan-kettering experience and a literature review. J Clin Oncol 16(12):3880-3889
12. Ludin A, Macklis RM (2000) Radiotherapy for pediatric genitourinary tumors. its role and long-term consequences. Urol Clin North Am 27(3):553-562
13. Roarty JD, McLean IW, Zimmerman LE (1988) Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 95(11):1583-1587
14. Kushner BH, Cheung NK (2005) Neuroblastoma - from genetic profiles to clinical challenge. N Engl J Med 353(21):2215-2217
15. Ordonez-Moran P, Larriba MJ, Pendas-Franco N, Aguilera O, Gonzalez-Sancho JM, Munoz A (2005) Vitamin D and cancer: An update of in vitro and in vivo data. Front Biosci 10:2723-2749
16. Lam HY, Schnoes HK, DeLuca HF (1974) 1alpha-hydroxyvitamin D2: A potent synthetic analog of vitamin D2. Science 186(4168):1038-1040
17. Sjoden G, Smith C, Lindgren U, DeLuca HF (1985) 1 alpha-hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 178(3):432-436
18. Albert DM, Kumar A, Strugnell SA, Darjatmoko SR, Lokken JM, Lindstrom MJ et al (2004) Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model. Arch Ophthalmol 122(9):1365-1369
19. Albert DM, Kumar A, Strugnell SA, Darjatmoko SR, Lokken JM, Lindstrom MJ et al (2004) Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models. Arch Ophthalmol 122(9):1357-1362
20. Dawson DG, Gleiser J, Zimbric ML, Darjatmoko SR, Lindstrom MJ, Strugnell SA et al (2003) Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice. Ophthalmology 110(4):835-839
21. Grostern RJ, Bryar PJ, Zimbric ML, Darjatmoko SR, Lissauer BJ, Lindstrom MJ et al (2002) Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model. Arch Ophthalmol 120(5):607-612
22. Albert DM, Plum LA, Yang W, Marcet M, Lindstrom MJ, Clagett-Dame M et al (2005) Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor vitamin D analog. J Steroid Biochem Mol Biol 97(1-2):165-172
23. Reddy CD, Patti R, Guttapalli A, Maris JM, Yanamandra N, Rachamallu A et al (2006) Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma. J Cell Biochem 97(1):198-206
24. Gumireddy K, Ikegaki N, Phillips PC, Sutton LN, Reddy CD (2003) Effect of 20-epi-1alpha,25-dihydroxyvitamin D3 on the proliferation of human neuroblastoma: Role of cell cycle regulators and the myc-Id2 pathway. Biochem Pharmacol 65(12):1943-1955
25. Helson L, Helson C (1985) Human neuroblastoma cells and 13-cis-retinoic acid. J Neurooncol 3(1):39-41
26. Nagai J, Yazawa T, Okudela K, Kigasawa H, Kitamura H, Osaka H (2004) Retinoic acid induces neuroblastoma cell death by inhibiting proteasomal degradation of retinoic acid receptor alpha. Cancer Res 64(21):7910-7917
27. Celli A, Treves C, Stio M (1999) Vitamin D receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation. Neurochem Int 34(2):117-124
28. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ (2002) Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Res 62(22):6756-6763
29. PE applied biosystems (2001) ABI prism 7700 sequence detection system: Relative quatitation of gene expression.user bulletin #2: Rev B, 36 pp
30. Sabet SJ, Darjatmoko SR, Lindstrom MJ, Albert DM (1999) Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors. Arch Ophthalmol 117(3):365-370
31. Zinser GM, McEleney K, Welsh J (2003) Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol Cell Endocrinol 200(1-2):67-80
32. Brown AJ (2001) Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38(5 Suppl 5):S3-S19
33. Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM et al (2004) Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43(5):877-890
34. Liu G, Wilding G, Staab MJ, Horvath D, Miller K, Dresen A et al (2003) Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin Cancer Res 9(11):4077-4083
35. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ (2002) Biologically relevant orthotopic neuroblastoma xenograft models: Primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 16(2):77-85
36. Albert DM, Marcus DM, Gallo JP, O'Brien JM (1992) The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Invest Ophthalmol Vis Sci 33(8):2354-2364
37. Veenstra TD, Londowski JM, Windebank AJ, Brimijoin S, Kumar R (1997) Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells. Brain Res Dev Brain Res 99(1):53-60
38. Moore TB, Koeffler HP, Yamashiro JM, Wada RK (1996) Vitamin D3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells. Clin Exp Metastasis 14(3):239-245
39. Audo I, Darjatmoko SR, Schlamp CL, Lokken JM, Lindstrom MJ, Albert DM et al (2003) Vitamin D analogues increase p53, p21, and apoptosis in a xenograft model of human retinoblastoma. Invest Ophthalmol Vis Sci 44(10):4192-4199
40. Albert DM, Scheef EA, Wang S, Mehraein F, Darjatmoko SR, Sorenson CM et al (2007) Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci 48(5):2327-2334
41. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL (2006) Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res 66(17):8565-8573
42. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL (2002) Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143(7):2508-2514
43. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87(3):214-220
44. Peng X, Jhaveri P, Hussain-Hakimjee EA, Mehta RG (2007) Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1{alpha}-hydroxyvitamin D5. Carcinogenesis 28(5):1000-1007
45. Abedin SA, Banwell CM, Colston KW, Carlberg C, Campbell MJ (2006) Epigenetic corruption of VDR signalling in malignancy. Anticancer Res 26(4A):2557-2566